المؤلفون: Leger, Sandy, Picard, Damien, Ingen-Housz-Oro, Saskia, Arnault, Jean-Philippe, Aubin, François, Carsuzaa, Francis, Chaumentin, Gilles, Chevrant-Breton, Jacqueline, Chosidow, Olivier, Crickx, Béatrice, D'incan, Michel, Dandurand, Michel, Debarbieux, Stéphane, Delaporte, Emmanuel, Dereure, Olivier, Doutre, Marie-Sylvie, Guillet, Gérard, Jullien, Denis, Kupfer, Ingrid, Lacour, Jean-Philippe

المصدر: Archives of Dermatology; Oct2012, Vol. 148 Issue 10, p1165-1172, 8p

مستخلص: Objective: To identify the prognostic factors of overall survival in a series of patients with paraneoplastic pemphigus (PNP). Design: Multicenter retrospective cohort study. Setting: Twenty-seven dermatology departments in France. Patients: A total of 53 patients (31 men and 22 women; median age, 59 years; age range, 30-88 years) were diagnosed as having PNP between 1992 and 2010. Main Outcome Measures: Overall Kaplan-Meier survival rates were estimated, and features associated with survival were assessed using univariate (log-rank test) and multivariate (Cox regression) analyses. Results: The study included 53 patients with PNP. Thirtysix patients (68%) died during the study. The 1-, 3-, and 5-year overall survival rates were 49%, 41%, and 38%, respectively. The main causes of death were infections (n=21) and evolution of neoplasia (n=6). In univariate analysis, the main detrimental prognostic factors identified were erythema multiforme-like skin lesions (P=.05) and histologic keratinocyte necrosis (P=.03). None of the 5 patients with Castleman disease died during the study. After adjustment for age and sex in multivariate analysis, erythema multiforme-like skin lesions remained predictive of fatal outcome, with a 2-fold increase in death rate (hazard ratio [HR], 2.3; 95% CI, 1.05-5.03; P=.04). The prognosis of patients with PNP was even poorer when erythema multiforme-like skin lesions were associated with severe skin or mucosal involvement at presentation (HR of death, 3.0; 95% CI, 1.01-8.92; P=.049). Conclusion: Patients with PNP with erythema multiforme- like skin lesions and histologic keratinocyte necrosis, especially when associated with extensive lesions at presentation, are likely to have a more severe and rapid fatal outcome and should be managed very carefully. [ABSTRACT FROM AUTHOR]

: Copyright of Archives of Dermatology is the property of American Medical Association and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Grange, Florent, Beylot-Barry, Marie, Courville, Phillipe, Maubec, Eve, Bagot, Martine, Vergier, Béatrice, Souteyrand, Pierre, Machet, Laurent, Dalac, Sophie, Esteve, Eric, Templier, Isabelle, Delaporte, Emmanuel, Avril, Marie-Françoise, Robert, Caroline, Dalle, Stephane, Laroche, Liliane, Delaunay, Michele, Joly, Pascal, Wechsler, Janine, Petrella, Tony

المصدر: Archives of Dermatology; Sep2007, Vol. 143 Issue 9, p1144-1150, 7p

مستخلص: Objectives: To describe clinicopathologic features and to identify prognostic factors in a large series of primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL LT), as defined in the recent World Health Organization-European Organization for Research and Treatment of Cancer classification of cutaneous lymphomas. Design: Retrospective multicenter study from the French Study Group on Cutaneous Lymphomas. Setting: Nineteen departments of dermatology in 10 regions of France. Patients: Sixty patients with a PCLBCL LT included in the registry of the French Study Group on Cutaneous Lymphomas. Main Outcome Measures: Age, sex, outcome, therapy, B symptoms, cutaneous extent, number of lesions, location (leg vs nonleg), serum lactate dehydrogenase level, and MUM-1 and Bcl-2 expression were recorded. Diseasespecific survival was used as the main end point. Prognostic factors were identified using a Cox proportional hazards model. Results: Primary cutaneous diffuse large B-cell lymphoma, leg type is characterized by a predilection for the leg (72%), a high proportion of Bcl-2 expression (85%), an advanced age at onset (mean age, 76 years), and frequent relapses and extracutaneous dissemination. The overall 5-year disease-specific survival rate was 41%. Location on the leg and multiple skin lesions were predictive of death in multivariate analysis. Although no variable related to therapy was significantly associated with survival, patients recently treated with combinations of anthracycline-containing chemotherapies and rituximab had a more favorable shortterm outcome. Conclusions: Primary cutaneous diffuse large B-cell lymphoma, leg type is a distinct entity with a poor prognosis, particularly in patients with multiple tumors on the legs. Despite the advanced age of many patients, the prognosis could be improved with combinations of anthracycline-containing chemotherapies and rituximab. [ABSTRACT FROM AUTHOR]

: Copyright of Archives of Dermatology is the property of American Medical Association and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Sais, Gemma, Vidaller, Antonio, Kano, Yoko, Shiohara, Tetsuo, Lebrun-Vignes, Bénédicte, Roujeau, Jean-Claude, Bernard, Philippe, Delaporte, Emmanuel, Joly, Pascal, Prost, Catherine, Vaillant, Loic, Herson, Serge, Chosidow, Olivier, Hoegl, Lois, Thoma-Greber, Eva, Poppinger, Jürgen, Röcken, Martin, Oyama, Masatoshi, Imaizumi, Tsutomu

المصدر: Archives of Dermatology; Jan1999, Vol. 135 Issue 1, p87, 8p

مصطلحات موضوعية: PRECANCEROUS conditions, DERMATOLOGY

مستخلص: Comments on a research article regarding the pathogenesis of exercise induced urticarial vasculitis lesions. Points and counterpoints raised by the critique; Reply made by authors on the reviewers' comments; Theoretical significance to dermatology.

المؤلفون: Viguier, Manuelle, Aubin, François, Delaporte, Emmanuel, Pagès, Cécile, Paul, Carle, Beylot-Barry, Marie, Goujon, Catherine, Rybojad, Michel, Bachelez, Hervé

المصدر: Archives of Dermatology; Dec2012, Vol. 148 Issue 12, p1423-1425, 3p

المؤلفون: Delaporte, Emmanuel, Gaveau, Didier J., Piette, Frederic A., Bergoënd, Henri A.

المصدر: Archives of Dermatology; August 1989, Vol. 125 Issue: 8 p1101-1104, 4p

مستخلص: • A 58-year-old woman suffering from rheumatoid arthritis complicated by a leukocytoclastic vasculitis had an acute febrile neutrophilic dermatosis (Sweet's syndrome) develop immediately after worsening of her arthritic condition. This association supports the hypothesis that immunologic abnormality is involved in the pathogenesis of Sweet's syndrome and raises the question of a possible common pathogenic pathway between neutrophilic dermatoses and leukocytoclastic vasculitis.(Arch Dermatol. 1989;125:1101-1104)

المؤلفون: Grange, Florent, Maubec, Eve, Bagot, Martine, Beylot-Barry, Marie, Joly, Pascal, Dalle, Stéphane, Delaporte, Emmanuel, Dereure, Olivier, Bachelez, Hervé, Vergier, Béatrice, Petrella, Tony, D'Incan, Michel

المصدر: Archives of Dermatology; Mar2009, Vol. 145 Issue 3, p329-330, 2p

المؤلفون: Humbert, Philippe, Aubin, François, Dupond, Jean Louis, Delaporte, Emmanuel

المصدر: Archives of Dermatology; July 1995, Vol. 131 Issue: 7 p850-851, 2p

مستخلص: We read the recent case report by Hulshof et al1 in the October 1994 issue of the Archives with interest. The authors described three patients with generalized morphea who were treated with calcitriol (1,25-dihydroxyvitamin D3) in an oral dose of 0.5 to 0.75 μg per day. After 3 to 7 months of treatment, the authors observed a beneficial effect on joint mobility and skin extensibility. Since our first report in 19902 demonstrating the beneficial effect of oral calcitriol in local- ized scleroderma, we conducted a study in 11 patients with systemic sclerosis and seven patients with morphea that also showed the efficacy of oral calcitriol. To date, after a 2- to 36-month treatment period, we confirm our promising data, as published in two recent reports.3-5 Taken together, these results suggest that a high dose of oral calcitriol (mean dose, 1.75 μg/d) may be a useful therapeutic